Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches.

Characterization of NSCLC subsets in which immune senescence is a risk factor for poor prognosis and poor therapeutic response might be very helpful in supporting the addition of senotherapeutics to conventional cancer therapy. This approach has the potential to improve disease outcome but more studies in this area are necessary.